Skip to main content

Search

Reset all filters
771 Result(s)
Sort by

Careers

Careers

Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
Oncology

Oncology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
digital_leader_award_2020

digital_leader_award_2020

Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
Congress Patient Benefit

Congress Patient Benefit

The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
Transforming Science Day Europe

Transforming Science Day Europe

Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.
Partnership canine oncology

Partnership canine oncology

The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Micardis®

Micardis®

Treatment of hypertension. For the reduction of the risk of myocardial infarction (heart attack), stroke or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take A
BIVF funding more than doubled to 250 M€

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Interview Dr Mehdi Shahidi

Interview Dr Mehdi Shahidi

Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Strategic-collaboration-with-EnaraBio

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.